Literature DB >> 14597609

Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: a study of the AML Study Group Ulm (AMLSG ULM).

Konstanze Döhner, Karen Tobis, Tobias Bischof, Stefan Hein, Richard F Schlenk, Stefan Fröhling, Hartmut Döhner.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14597609     DOI： 10.1182/blood-2003-08-2654

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  13 in total

Review 1.  Role of transcription factors C/EBPalpha and PU.1 in normal hematopoiesis and leukemia.

Authors:  Steffen Koschmieder; Frank Rosenbauer; Ulrich Steidl; Bronwyn M Owens; Daniel G Tenen
Journal:  Int J Hematol       Date:  2005-06       Impact factor: 2.490

2.  Inactivation of PU.1 in adult mice leads to the development of myeloid leukemia.

Authors:  Donald Metcalf; Aleksandar Dakic; Sandra Mifsud; Ladina Di Rago; Li Wu; Stephen Nutt
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  Runx1 deletion or dominant inhibition reduces Cebpa transcription via conserved promoter and distal enhancer sites to favor monopoiesis over granulopoiesis.

Authors:  Hong Guo; Ou Ma; Nancy A Speck; Alan D Friedman
Journal:  Blood       Date:  2012-03-26       Impact factor: 22.113

4.  A two-mutation model of radiation-induced acute myeloid leukemia using historical mouse data.

Authors:  Fieke Dekkers; Harmen Bijwaard; Simon Bouffler; Michele Ellender; René Huiskamp; Christine Kowalczuk; Emmy Meijne; Marjolein Sutmuller
Journal:  Radiat Environ Biophys       Date:  2010-09-15       Impact factor: 1.925

Review 5.  Oncogenic pathways of AML1-ETO in acute myeloid leukemia: multifaceted manipulation of marrow maturation.

Authors:  Kamaleldin E Elagib; Adam N Goldfarb
Journal:  Cancer Lett       Date:  2006-11-27       Impact factor: 8.679

6.  Genome wide molecular analysis of minimally differentiated acute myeloid leukemia.

Authors:  Fernando P G Silva; Inês Almeida; Bruno Morolli; Geeske Brouwer-Mandema; Hans Wessels; Rolf Vossen; Harry Vrieling; Erik W A Marijt; Peter J M Valk; Hanneke C Kluin-Nelemans; Wolfgang R Sperr; Wolf-Dieter Ludwig; Micheline Giphart-Gassler
Journal:  Haematologica       Date:  2009-09-22       Impact factor: 9.941

7.  Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

Authors:  Daniel C Link; Ghada Kunter; Yumi Kasai; Yu Zhao; Tracie Miner; Michael D McLellan; Rhonda E Ries; Deepak Kapur; Rakesh Nagarajan; David C Dale; Audrey Anna Bolyard; Laurence A Boxer; Karl Welte; Cornelia Zeidler; Jean Donadieu; Christine Bellanné-Chantelot; James W Vardiman; Michael A Caligiuri; Clara D Bloomfield; John F DiPersio; Michael H Tomasson; Timothy A Graubert; Peter Westervelt; Mark Watson; William Shannon; Jack Baty; Elaine R Mardis; Richard K Wilson; Timothy J Ley
Journal:  Blood       Date:  2007-05-09       Impact factor: 22.113

Review 8.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490

9.  The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias.

Authors:  Vincent-Philippe Lavallée; Irène Baccelli; Jana Krosl; Brian Wilhelm; Frédéric Barabé; Patrick Gendron; Geneviève Boucher; Sébastien Lemieux; Anne Marinier; Sylvain Meloche; Josée Hébert; Guy Sauvageau
Journal:  Nat Genet       Date:  2015-08-03       Impact factor: 38.330

10.  Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates.

Authors:  Xiaorong Gu; Quteba Ebrahem; Reda Z Mahfouz; Metis Hasipek; Francis Enane; Tomas Radivoyevitch; Nicolas Rapin; Bartlomiej Przychodzen; Zhenbo Hu; Ramesh Balusu; Claudiu V Cotta; David Wald; Christian Argueta; Yosef Landesman; Maria Paola Martelli; Brunangelo Falini; Hetty Carraway; Bo T Porse; Jaroslaw Maciejewski; Babal K Jha; Yogen Saunthararajah
Journal:  J Clin Invest       Date:  2018-07-17       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.